异甘草酸镁联合恩替卡韦治疗慢性乙型肝炎肝硬化的疗效观察

Observation on the efficacy of magnesium isoglycyrrhizinate combined with entecavir in the treatment of chronic hepatitis B cirrhosis

目的探讨异甘草酸镁联合恩替卡韦治疗慢性乙型肝炎肝硬化的临床疗效。方法选择2021年1月至2024年3月医院收治的78例慢性乙型肝炎肝硬化患者,以随机方法分组,每组39例。对照组采用恩替卡韦治疗,观察组在此基础上结合异甘草酸镁治疗。对两组临床疗效、肝功能与肝纤维化指标、不良反应进行比较。结果观察组治疗总疗效率高于对照组,P<0.05。治疗后观察组AST、ALT、TBIL、HA、PC-Ⅲ、LN、Ⅳ-C均较对照组低,P<0.05。观察组不良反应发生率与对照组比较,P>0.05。结论慢性乙型肝炎肝硬化患者联合采用异甘草酸镁与恩替卡韦治疗可获取良好疗效,且对患者肝功能改善作用明显,同时可抑制肝纤维化进程,不增加药物不良反应。

Objective:To Objective To explore the clinical efficacy of magnesium isoglycyrrhizinate combined with entecavir in the treatment of chronic hepatitis B cirrhosis.Methods:78 patients with chronic hepatitis B cirrhosis admitted to the hospital from January 2021 to March 2024 were randomly divided into two groups,with 39 cases in each group.The control group was treated with entecavir,and the observation group was treated with magnesium isoglycyrrhizinate on this basis.The clinical efficacy、liver function、liver fibrosis index and adverse reactions were compared between the two groups.Results:The total curative rate of the observation group was higher than that of the control group,P<0.05.After treatment,AST、ALT、TBIL、HA、PC-Ⅲ、LN andⅣ-C in the observation group were lower than those in the control group,P<0.05.Compared with the control group,the incidence of adverse reactions in the observation group was,P>0.05.Conclusion:The combined treatment of magnesium isoglycyrrhizinate and entecavir in patients with chronic hepatitis B cirrhosis can achieve good curative effect,and can obviously improve the liver function of patients,and inhibit the process of liver fibrosis without increasing adverse drug reactions.